Anti-epileptic drugs are prescribed for patients who suffer from seizures. The major symptom of epilepsy is repeated seizures, which are sudden bursts of electrical activity in the brain that temporarily affects the functioning of the brain. Some seizures cause the body to jerk and shake, while others cause problems such as loss of awareness or unusual sensations. Anti-epileptic drugs (AEDs) include a diverse class of medications that are increasingly used for conditions apart than epilepsy such as migraine prophylaxis, neuropathic pain, and bipolar disorder. The drugs prescribed for anti-epileptics are categorized in three generations. Each generation denotes a different specification. The first generation drugs includes Bromide, Phenobarbital, Primidone, Carbamazepine and others is between “1857-1970”, second generation drugs include Felbamate, Lamotrigine, Levetiracetam, and others is between “1989-2007” and third generation drugs includes Lacosamide, Eslicarbazepine Acetate, Clobazam and others is between “2010-2018”.
Anti-epileptic drugs Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID 19) pandemic and lockdowns in various countries across the globe have impacted the financial status of business across all sectors. The private healthcare sector is one the sectors which has been majorly impacted by the COVID-19 pandemic. The lockdown in various countries due to COVID-19 pandemic has created an economic burden on the private healthcare sector. According to the Indian Journal of Medical Sciences published report in 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to unavailability of trial site staff, restrictions for travelling, investigational product availability, and others. According to National Center for Biotechnology Information (NCBI) published report on April 29, 2020, many clinical trials suspended the trial enrollment, in order to minimize the risk of contracting COVID-19, and this has led to the delay in the activation of new clinical trial. Moreover, many companies have already missed the follow-up for the patients already in trials. Product development has experienced disruption to adjust to remote-work environments and lab capacity is reduced. Clinical trials are also being severely affected with disruptions in both new enrollment and in keeping existing patients on therapies. According to the clinicaltrial.gov, as of April 2020, there were more than 2,850 trials and approximately 900,000 patients enrolled at trial sites in regions that were in partial or complete lockdown due to COVID-19 restrictions. While, the R&D labs are currently operating at below 50% of the normal capacity across the globe. Many companies with drug candidates for the treatment of epilepsy are prioritizing clinical trials based on their significant evidence of clinical activity and withheld early-phase clinical trials, namely Phase I trials. Many research centers have decided to freeze new trials and have stopped inpatient studies. Different pharmaceutical companies have also decided to delay the start of new clinical trials, suspended enrollment in some trials, and have postponed the initiation of new sites in the case of trials continuing enrollment.
Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the global anti-epileptic drugs market during the forecast period.
The global anti-epileptic drugs market is estimated to be valued at US$ 6,644.7 million in 2021 and is expected to exhibit a CAGR of 1.4% during the forecast period (2021-2028).
|Base Year:||2020||Market Size in 2021:||US$ 6,644.7 Mn|
|Historical Data for:||2018 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||1.4 %||2028 Value Projection:||US$ 7,344.9 Mn|
Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., Angelini S.p.a, Sun Pharmaceutical Industries Ltd., UCB S.A, Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., and Bausch Health Companies Inc.
|Restraints & Challenges:||
Figure 1. Global Anti-epileptic Drugs Market Share (%), By Generation, 2021-2028
Increasing collaboration by key players and increasing number of product approvals by regulatory bodies are expected to drive growth of global anti-epileptic drugs market.
Major factors assisting the market growth during the forecast period include the rising number of collaborations by key players in the market. For instance, in May 2021, Epilepsy Foundation, a U.S.-based non-profit national foundation, entered into a collaboration with Eisai Inc., a Japanese pharmaceutical company, to develop the Epilepsy Digital Experience Navigator (EDEN), a platform designed to empower people with epilepsy, their caregivers, and clinicians, to use data to better understand and improve the epilepsy journey.
Furthermore, market key players are focused on gaining approvals from regulatory bodies, this is expected to drive the growth of global anti-epileptic drugs market. For instance, in July 2019, Pfizer, Inc. announced the approval of the U.S Food and Drug Administration for first generics of Lyrica (pregabalin) as an adjunctive therapy for the treatment of partial onset seizures in patients of 17 years of age and older.
Global Anti-epileptic Drugs Market – Restraints
Growth of the global anti-epileptic drugs market is expected to be hampered over the forecast period, owing to adoption of alternative treatment for children with epilepsy. Complementary and alternative medicine (CAM), which include ketogenic diet, modified Atkins diet (MAD), and the low glycemic index treatment (LGIT) are widely used for the treatment of epilepsy among children, in addition to AEDs. For instance, according to the Clinical Nutrition Research (a research study conducted to examine the consumption of nutritional supplements used in various treatments) in 2016, around 30% of the children suffering from uncontrolled epileptic seizures were untreated worldwide, where a ketogenic diet (KD) could be used as an alternative medical treatment for these children, these factors are expected to restrain the global anti-epileptic drugs market growth.
Figure 2. Global Anti-epileptic Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2028
Global Anti-epileptic Drugs Market - Compe titive Landscape
Key players operating in the global anti-epileptic drugs market are Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., Angelini S.p.a, Sun Pharmaceutical Industries Ltd., UCB S.A, Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., and Bausch Health Companies Inc.
Epilepsy is a chronic disorder that affects the brain and causes frequent seizures. Seizures are bursts of electrical activity in the brain that temporarily affects its functioning. Epilepsy can start at any age, but usually starts either in childhood or in people over the age of 60. There are several tests conducted to determine the activity in the brain. An electroencephalogram (EEG) is conducted on epilepsy patients to check for unusual electrical activities in the brain. A brain scan is also used to spot problems in the brain that is sometimes caused due to epilepsy such as an unusual growth (brain tumour), damage to the brain, and scarring in the brain. Magnetic resonance imaging (MRI) scan is also used to conduct the brain scan in patients suffering from epilepsy. It uses magnetic fields and radio waves to create an image of the brain. Anti-epileptic drugs are also used in the treatment of epilepsy, which are categorized into three generations.
Increasing number of product launches is expected to drive the global anti-epileptic drug market. For instance, in January 2016, Mylan N.V. launched Felbamate tablets USP in 400 mg and 600 mg dosages. Felbamate tablets are the generic version of Felbatol tablets used for the treatment of epilepsy. These are recommended for the treatment of partial seizures, with or without secondary generalizations in adults with epilepsy and in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.
However, growth of the global anti-epileptic drug market is expected to be hampered over the forecast period, owing to potential side effects of the anti-epileptic drugs. For instance, according to the Journal of Family Practice, the side effects of anti-epileptic drugs include, the medication Phenytoin, which is used for treating epilepsy patients causes a pattern of defects collectively called the Fetal Hydantoin Syndrome (FHS), which is characterized by variable degrees of hypoplasia and ossification of the distal phalanges and craniofacial abnormalities.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.